We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+18.8%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.68B
AUM Growth
+$421M
Cap. Flow
+$302M
Cap. Flow %
11.29%
Top 10 Hldgs %
68.02%
Holding
83
New
12
Increased
16
Reduced
6
Closed
11

Top Buys

Rank Stock Value
1
ALEC icon
Alector
ALEC
+$68.6M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$52.4M
3
RLAY icon
Relay Therapeutics
RLAY
+$34.9M
4
RCUS icon
Arcus Biosciences
RCUS
+$32.5M
5
JANX icon
Janux Therapeutics
JANX
+$31.4M

Top Sells

Rank Stock Value
1
ELDN icon
Eledon Pharmaceuticals
ELDN
+$11.9M
2
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$10.5M
3
NGNE icon
Neurogene
NGNE
+$8.45M
4
ACIU icon
AC Immune
ACIU
+$6.91M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$5.09M

Sector Composition

Rank Sector Weight
1 Healthcare 98.93%
2 Financials 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLT icon
51
Bolt Biotherapeutics
BOLT
$8.59M
$2.32M 0.09%
7,500
– –
BCAB icon
52
BioAtla
BCAB
$6.14M
$2.12M 0.08%
1,000
– –
BLSA
53
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.11M 0.08%
200,000
– –
MLTX icon
54
MoonLake Immunotherapeutics
MLTX
$1.59B
$2.07M 0.08%
200,000
– –
FVAM
55
DELISTED
5:01 Acquisition Corp
FVAM
$1.99M 0.07%
200,000
– –
SRZN icon
56
Surrozen
SRZN
$257M
$1.99M 0.07%
+13,333
New +$1.98M
EUCR
57
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$1.97M 0.07%
200,000
– –
FLAC
58
DELISTED
Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares
FLAC
$1.96M 0.07%
+200,495
New +$1.98M
PMVP icon
59
PMV Pharmaceuticals
PMVP
$68.3M
$1.71M 0.06%
50,000
– –
ARYD
60
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$1.61M 0.06%
150,000
– –
RPTX
61
DELISTED
Repare Therapeutics
RPTX
$1.56M 0.06%
50,000
– –
PRDS
62
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$1.5M 0.06%
150,000
– –
MGTX icon
63
MeiraGTx Holdings
MGTX
$1.13B
$1.47M 0.05%
94,819
– –
CMAXW
64
DELISTED
CareMax, Inc. Warrant
CMAXW
$1.29M 0.05%
100,000
– –
TMPM
65
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$989K 0.04%
100,000
– –
SRZNW icon
66
Surrozen Inc Warrant
SRZNW
$662K 0.02%
+66,665
New +$73K
EUCRW
67
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
$656K 0.02%
66,666
– –
FLACW
68
DELISTED
Frazier Lifesciences Acquisition Corporation Warrant
FLACW
$651K 0.02%
+66,665
New +$66.5K
KNTE
69
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$582K 0.02%
25,000
– –
OMEG
70
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$498K 0.02%
50,000
– –
FSTX
71
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$395K 0.01%
46,000
– –
TMPMW
72
DELISTED
Turmeric Acquisition Corp. Warrant
TMPMW
$330K 0.01%
33,333
– –
ELDN icon
73
Eledon Pharmaceuticals
ELDN
$298M
– –
-1,115,721
Closed -$11.9M
PRTA icon
74
CALL
Prothena Corp
PRTA
$454M
– –
-250,000
Closed -$6.28M
WHWK
75
Whitehawk Therapeutics
WHWK
$187M
– –
-138,185
Closed -$2.67M
1 2
3
4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $2.36B AUM 68.36% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

EcoR1 Capital's Q2 2021 Portfolio in Review

As of Q2 2021, EcoR1 Capital held 83 positions worth $2.68B, up 19% from $2.25B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital deployed $302M of net new capital in Q2 2021, opening 12 new positions and adding to 16 existing holdings. Its largest new stake was Janux Therapeutics: 1,411,975 shares worth $35.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Neurogene, an estimated $8.45M trimmed.

  • EcoR1 Capital's largest Q2 2021 buy was Janux Therapeutics: 1,411,975 shares worth $35.2M.
  • EcoR1 Capital added most to Alector in Q2 2021, an estimated $68.6M increase.
  • EcoR1 Capital's biggest Q2 2021 reduction was Neurogene, cutting an estimated $8.45M.
  • EcoR1 Capital fully exited Eledon Pharmaceuticals in Q2 2021, selling an estimated $11.9M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $2.68B portfolio in Q2 2021.
  • EcoR1 Capital opened 12 new positions and closed 11 in Q2 2021.
  • EcoR1 Capital's portfolio value rose 19% quarter-over-quarter to $2.68B.

Based on EcoR1 Capital's 13F filing for Q2 2021, filed 16 Aug 2021.